+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cancer Monoclonal Antibodies"

From
From
From
Monoclonal Antibodies for Oncology: Global Markets - Product Thumbnail Image

Monoclonal Antibodies for Oncology: Global Markets

  • Report
  • February 2026
  • 229 Pages
  • Global
From
Cancer & Antibody Conjugates Patent Landscape Analysis 2025 - Product Thumbnail Image

Cancer & Antibody Conjugates Patent Landscape Analysis 2025

  • Report
  • December 2025
  • 100 Pages +
  • Global
Monoclonal Antibody Discovery and Analysis Market Report 2022-2032 - Product Thumbnail Image

Monoclonal Antibody Discovery and Analysis Market Report 2022-2032

  • Report
  • December 2022
  • 437 Pages
  • Global
From
US Bispecific Antibodies Market & Clinical Pipeline Insight 2028 - Product Thumbnail Image

US Bispecific Antibodies Market & Clinical Pipeline Insight 2028

  • Drug Pipelines
  • August 2023
  • 580 Pages
  • United States
From
Biopharmaceuticals - A Global Market Overview - Product Thumbnail Image

Biopharmaceuticals - A Global Market Overview

  • Report
  • February 2025
  • 225 Pages
  • Global
From
From
From
From
From
From
From
Loading Indicator

Cancer Monoclonal Antibodies (mAbs) are a type of oncology drug used to treat cancer. They are a type of biologic therapy, which means they are made from living cells. mAbs are designed to target specific proteins on cancer cells, which can help to slow or stop the growth of the cancer. They can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. mAbs can be used to treat a variety of cancers, including breast, lung, and colorectal cancer. The Cancer Monoclonal Antibodies market is a rapidly growing segment of the oncology drugs market. mAbs are becoming increasingly popular due to their ability to target specific proteins on cancer cells, which can help to reduce side effects and improve outcomes. Additionally, mAbs are often more cost-effective than other treatments, making them attractive to healthcare providers. Some of the major companies in the Cancer Monoclonal Antibodies market include Roche, Merck, Bristol-Myers Squibb, Amgen, and Novartis. Show Less Read more